Shenzhen Hank Bioengineering Institute Report issue

Government Phase 2
Founded: Shenzhen China (2013)

Organization Overview

First Clinical Trial
2016
NCT02849366
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Shenzhen Hank Bioengineering Institute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Laryngeal Neoplasms (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Melanoma (Phase 2)

Nasopharyngeal Carcinoma (Phase 2)

Nasopharyngeal Neoplasms (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pharyngeal Neoplasms (Phase 2)

Sarcoma (Phase 2)

Tongue Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 25
  • # of Trial APIs: 7